DrugId:  1
1. Name:  Alvircept Sudotox
2. Groups:  Investigational
3. Description:  Alvircept Sudotox has been used in trials studying the treatment of HIV Infections.
4. Indication:  Not Available
DrugId:  2
1. Name:  BG-777
2. Groups:  Investigational
3. Description:  BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
4. Indication:  Investigated for use/treatment in cytomegalovirus (CMV) retinitis, HIV infection, influenza, and pneumonia.
DrugId:  3
1. Name:  PRO-542
2. Groups:  Investigational
3. Description:  PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. 
4. Indication:  Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DrugId:  4
1. Name:  Diethylhomospermine
2. Groups:  Investigational
3. Description:  Diethylhomospermine has been used in trials studying the treatment of Diarrhea and HIV Infections.
4. Indication:  Not Available
DrugId:  5
1. Name:  Fosdevirine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in HIV infection and acquired immune deficiency syndrome (AIDS) and aids-related infections.
DrugId:  6
1. Name:  Emtricitabine
2. Groups:  Approved, Investigational
3. Description:  Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. Emtricitabine is an analogue of cytidine. The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA.
4. Indication:  Indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and for postexposure prophylaxis of HIV infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus.
DrugId:  7
1. Name:  Tipranavir
2. Groups:  Approved, Investigational
3. Description:  Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. It is administered with ritonavir in combination therapy to treat HIV infections.
4. Indication:  For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
DrugId:  8
1. Name:  PRO 2000
2. Groups:  Investigational
3. Description:  PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people.
4. Indication:  Investigated for use/treatment in HIV prevention, prevention of stdis, and vaginal infection.
DrugId:  9
1. Name:  Dexelvucitabine
2. Groups:  Investigational
3. Description:  Dexelvucitabine has been used in trials studying the treatment of HIV Infections and Human Immunodeficiency Virus.
4. Indication:  Not Available
DrugId:  10
1. Name:  Ibalizumab
2. Groups:  Approved, Investigational
3. Description:  Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [8, 5].This drug was approved in March 2018 for the management of treatment-resistant HIV [5].
4. Indication:  Indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in highly treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen [FDA Label].The approval of Trogarzo was supported by a clinical trial of 40 treatment-experienced adults with MDR HIV-1 infection who persistently had elevated levels of HIV RNA in their blood despite heavy antiretroviral therapy. The majority of study patients had previously been treated with â‰¥10 antiretroviral medications [5].
DrugId:  11
1. Name:  Binetrakin
2. Groups:  Investigational
3. Description:  Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Mitoguazone
2. Groups:  Investigational
3. Description:  Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.
4. Indication:  Not Available
DrugId:  13
1. Name:  Racivir
2. Groups:  Investigational
3. Description:  Racivir, also known as RCV, is an oxothiolane nucleoside reverse transcriptase inhibitor similar to emtricitabine and lamivudine. Racivir is a 50:50 mixture of emtricitabine Emtricitabine and its positive enantiomer. Racivir has been used in trials studying the prevention of HIV Infections.
4. Indication:  Not Available
DrugId:  14
1. Name:  Lobucavir
2. Groups:  Investigational
3. Description:  Lobucavir has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
4. Indication:  Not Available
DrugId:  15
1. Name:  Tifuvirtide
2. Groups:  Investigational
3. Description:  Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast track designation from the FDA and is in Phase I/II clinical testing.
4. Indication:  Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
DrugId:  16
1. Name:  PAC-113
2. Groups:  Investigational
3. Description:  PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction.
4. Indication:  Investigated for use/treatment in candidiasis, fungal infections, and saliva and salivary gland dysfunction.
DrugId:  17
1. Name:  Talviraline
2. Groups:  Investigational
3. Description:  Talviraline has been used in trials studying the treatment of HIV Infections.
4. Indication:  Not Available
DrugId:  18
1. Name:  Timonacic
2. Groups:  Investigational
3. Description:  Timonacic has been used in trials studying the treatment of HIV Infections.
4. Indication:  Not Available
DrugId:  19
1. Name:  Glycovir
2. Groups:  Investigational
3. Description:  Glycovir has been used in trials studying the treatment of HIV Infections.
4. Indication:  Not Available
DrugId:  20
1. Name:  Amdoxovir
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in HIV infection and acquired immune deficiency syndrome (AIDS) and aids-related infections.
DrugId:  21
1. Name:  Emivirine
2. Groups:  Investigational
3. Description:  Emivirine has been used in trials studying the treatment of HIV Infections.
4. Indication:  Not Available
DrugId:  22
1. Name:  Letrazuril
2. Groups:  Investigational
3. Description:  Letrazuril has been used in trials studying the treatment of HIV Infections and Cryptosporidiosis.
4. Indication:  Not Available
DrugId:  23
1. Name:  TNP-470
2. Groups:  Investigational
3. Description:  O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms.
4. Indication:  Not Available
DrugId:  24
1. Name:  Dapivirine
2. Groups:  Investigational
3. Description:  Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.
4. Indication:  Not Available
DrugId:  25
1. Name:  CP1-1189
2. Groups:  Investigational
3. Description:  CPI-1189 has been used in trials studying the treatment of HIV Infections and AIDS Dementia Complex.
4. Indication:  Not Available
